MPG.eBooks - Search Results - (adolescence OR adolescents)

1

Guidelines and recommendations for ADHD in children and adolescents

Published 2011

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

2

Guidelines and recommendations for ADHD in children and adolescents

Published 2011

Canadian Agency for Drugs and Technologies in Health

“...Medications to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents...”

Read Now

3

Nusinersen for adolescents and adults with spinal muscular atrophy : a review of clinical effectiveness

by Janoudi, Ghayath, McCormack, Suzanne
Published 2020

Canadian Agency for Drugs and Technologies in Health

Read Now

4

Combination atypical antipsychotics in adolescents or adults with bipolar disorder with psychotic...

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

5

Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

6

Omalizumab (Xolair) : treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria

Published 2015

Canadian Agency for Drugs and Technologies in Health

“... of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain...”

Read Now

7

Clinical review report: Cyclosporine (VERKAZIA) (Santen Canada Inc.) : indication : treatment of severe vernal keratoconjunctivitis in children from four years of age through adole...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

8

Optimal use recommendations for atypical antipsychotics : combination and high-dose treatment strategies in adolescents and adults with schizophrenia

Published 2011

Canadian Agency for Drugs and Technologies in Health

“... of atypical antipsychotic (AAP) combination and high-dose treatment strategies in adolescents and adults...”

Read Now

9

CADTH Canadian drug expert committee recommendation: Cyclosporine 0.1% (Verkazia -- Santen Canada Inc.) : indication : treatment of severe vernal keratoconjunctivitis in children f...

Published 2019

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

10

Clinical review report: Lanadelumab (Takhzyro) (Shire pharma Canada ULC) : indication : for routine prevention of attacks of hereditary angioedema in adolescents and adults

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

11

Clinical review report: Cyclosporine (VERKAZIA) (Santen Canada Inc.) : indication : treatment of severe vernal keratoconjunctivitis in children from four years of age through adole...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... through adolescence...”

Read Now

12

Pharmacoeconomic review report: Cyclosporine (Verkazia) (Santen Canada inc.) : indication: treatment of severe vernal keratoconjunctivitis in children from four years of age throug...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Read Now

13

Pharmacoeconomic review report: Cyclosporine (Verkazia) (Santen Canada inc.) : indication: treatment of severe vernal keratoconjunctivitis in children from four years of age throug...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Read Now

14

Clinical review report: Lanadelumab (Takhzyro) (Shire pharma Canada ULC) : indication : for routine prevention of attacks of hereditary angioedema in adolescents and adults

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... for the routine prevention of attacks of hereditary angioedema in adolescents and adults...”

Read Now

15

Pharmacoeconomic review report: Lanadelumab (Takhzyro) (Shire pharma Canada ULC) : indication : for the routine prevention of attacks of hereditary angioedema in adolescents and ad...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... of hereditary angioedema (HAE). It is indicated for the routine prevention of attacks of HAE in adolescents...”

Read Now

16

Pharmacoeconomic review report: Lanadelumab (Takhzyro) (Shire pharma Canada ULC) : indication : for the routine prevention of attacks of hereditary angioedema in adolescents and ad...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... of hereditary angioedema (HAE). It is indicated for the routine prevention of attacks of HAE in adolescents...”

Read Now

17

Pharmacological interventions for chronic pain in pediatric patients : a review of guidelines

by Banerjee, Srabani, Butcher, Robyn
Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

18

Antipsychotics for pediatric patients : a review of the clinical effectiveness, safety, and guidelines

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

19

Antipsychotics for pediatric patients : a review of the clinical effectiveness, safety, and guidelines

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Adolescent...”

Read Now

20

Human growth hormone treatment for Prader-Willi syndrome in adolescent and adult patients: clinical evidence, safety, and guidelines

Published 2015

CADTH Rapid Response Service

Subjects: “...Adolescent...”

Narrow Search